Thrivent Financial For Lutherans Kura Oncology, Inc. Transaction History

Thrivent Financial For Lutherans

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$8.44 - $11.86 $225,440 - $316,792	-26,711 Reduced 40.36%	39,465 $359,000
Q2 2023 Aug 14, 2023	SELL	$9.62 - $13.99 $104,357 - $151,763	-10,848 Reduced 14.08%	66,176 $700,000
Q4 2022 Feb 08, 2023	SELL	$11.23 - $16.9 $720,977 - $1.08 Million	-64,201 Reduced 45.46%	77,024 $956,000
Q3 2022 Nov 14, 2022	BUY	$12.01 - $19.45 $621,373 - $1.01 Million	51,738 Added 57.82%	141,225 $1.93 Million
Q2 2022 Aug 16, 2022	BUY	$10.71 - $18.33 $958,405 - $1.64 Million	89,487 New	89,487 $1.64 Million
Q3 2021 Nov 15, 2021	SELL	$15.42 - $21.72 $220,506 - $310,596	-14,300 Closed	0 $0
Q2 2021 Aug 19, 2021	SELL	$20.85 - $29.88 $642,742 - $921,110	-30,827 Reduced 68.31%	14,300 $298,000
Q1 2021 May 17, 2021	SELL	$24.75 - $39.14 $768,561 - $1.22 Million	-31,053 Reduced 40.76%	45,127 $1.28 Million
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $2.21 Million - $3.17 Million	76,180 New	76,180 $2.49 Million

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.